

REGISTERED NUMBER: 01506034 (England and Wales)

FORUM BIOSCIENCE HOLDINGS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2015

FRIDAY



A58UM3O9

A14

10/06/2016

#316

COMPANIES HOUSE

Mazars LLP
The Pinnacle
160 Midsummer Boulevard
Milton Keynes
MK9 1FF

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

FORUM BIOSCIENCE HOLDINGS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2015

DIRECTOR: H Van Der Wal

SECRETARY: N Copp

REGISTERED OFFICE: Crown House
2-8 Gloucester Road
Redhill
Surrey
RH1 1FH

REGISTERED NUMBER: 01506034 (England and Wales)

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

BALANCE SHEET
31 DECEMBER 2015

	Notes	2015 £	2014 £
FIXED ASSETS			
Investments	2	4	4
CREDITORS			
Amounts falling due within one year		<u>2</u>	<u>2</u>
NET CURRENT LIABILITIES		<u>(2)</u>	<u>(2)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>2</u>	<u>2</u>
CAPITAL AND RESERVES			
Called up share capital	3	<u>2</u>	<u>2</u>
SHAREHOLDERS' FUNDS		<u>2</u>	<u>2</u>

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the year ended 31 December 2015.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2015 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved and authorised for issue by the director on 18th May 2016 and were signed by:



H Van Der Wal - Director

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2015

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015) and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Transition to FRS 102 'The Financial Reporting Standard Applicable in the UK and Republic of Ireland'

The financial statements for the year ended 31 December 2015 are the company's first financial statements that comply with FRS 102. The company's date of transition to FRS 102 is 1 January 2014. The company has taken advantage of the transitional exemption permitted under paragraph 35.10(m) which allows for the company, because it was dormant at 1 January 2014 and for each subsequent financial year, to retain its accounting policies for reported assets, liabilities and equity at the date of transition until there is any change in those balances or the company undertakes new transactions. Accordingly, there are no transitional adjustments arising for the company from transition to FRS 102 that affects its previously reported financial position or performance.

Preparation of consolidated financial statements

The financial statements contain information about Forum Bioscience Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its parent, Forum Products Holdings Limited, a company registered in England and Wales.

2. FIXED ASSET INVESTMENTS

	Investments other than loans £
COST	
At 1 January 2015	
and 31 December 2015	<u>4</u>
NET BOOK VALUE	
At 31 December 2015	<u><u>4</u></u>
At 31 December 2014	<u><u>4</u></u>

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Forum Products (Ireland) Limited

Nature of business: Dormant

	% holding	2015 £	2014 £
Class of shares:	100.00		
Ordinary			
Aggregate capital and reserves		<u><u>2</u></u>	<u><u>2</u></u>

Quantum Generics Limited

Nature of business: Dormant

	% holding	2015 £	2014 £
Class of shares:	100.00		
Ordinary			
Aggregate capital and reserves		<u><u>2</u></u>	<u><u>2</u></u>

FORUM BIOSCIENCE HOLDINGS LIMITED (REGISTERED NUMBER: 01506034)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2015

3. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2015 £	2014 £
2	Ordinary	1	<u>2</u>	<u>2</u>

4. ULTIMATE PARENT COMPANY

The company's immediate parent undertaking is Forum Products Holdings Limited a company registered in England and Wales. The company's ultimate parent undertaking is H.L. Barentz B.V. a company registered in The Netherlands.